Rapid identification of antigen-specific TCRs for cancer immunotherapy
Authors:
Open Access
- 1 January 2026
- journal article
- Published by Biophysical Society of China in Biophysics Reports
- Vol. 12 (2) , 100-115
Abstract
T cell receptors (TCRs) can recognize peptides presented by major histocompatibility complex (MHC) molecules, referred to as HLA in humans, which enables the targeted eradication of tumor cells expressing specific antigens. In recent years, TCR-engineered T cell (TCR-T) cell therapy has demonstrated substantial advancements in clinical trials targeting solid tumors. Notably, in August 2024, the U.S. FDA approved the first TCR-T drug for the treatment of advanced synovial sarcoma, representing a pivotal milestone in the field. For the development of TCR-T therapy, identifying tumor-associated antigen epitopes and high-functional TCRs are critical. Here, we present a comprehensive protocol outlining the process of identification of immunogenic epitopes and the efficient screening of antigen-specific TCRs from HLA transgenic mice. Additionally, the protocol encompasses methodologies for TCR-T cell preparation and their functional evaluation in vitro. These approaches provide a robust framework for advancing the development of tumor-specific TCRs and fostering the clinical translation of TCR-T therapies.Keywords
This publication has 36 references indexed in Scilit:
- Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trialNature Medicine, 2023
- Neoantigen T-Cell Receptor Gene Therapy in Pancreatic CancerNew England Journal of Medicine, 2022
- T cell receptor (TCR) signaling in health and diseaseSignal Transduction and Targeted Therapy, 2021
- T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytesNature Biotechnology, 2021
- Immunotherapy of HBV-related advanced hepatocellular carcinoma with short-term HBV-specific TCR expressed T cells: results of dose escalation, phase I trialHepatology International, 2021
- TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancersNature Medicine, 2021
- A guide to cancer immunotherapy: from T cell basic science to clinical practiceNature Reviews Immunology, 2020
- Driving T-cell immunotherapy to solid tumorsNature Biotechnology, 2018
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient ColitisMolecular Therapy, 2011
- PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sortingCancer Immunology, Immunotherapy, 2007